[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579836":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":68,"collaborators":72,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":37,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":37,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":42,"whyStopped":37,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MBF100","EXPERIMENTAL","Patients receive condoning regimen with melphalan (100mg\u002Fm2) with busulfan and fludarabine.",[13],"Drug: melphalan",{"label":15,"type":16,"description":17,"interventionNames":18},"MBF140","ACTIVE_COMPARATOR","Patients receive condoning regimen with melphalan (140mg\u002Fm2) with busulfan and fludarabine.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","melphalan","conditioning regimen with melphalan, busulfan and fludarabine",[9,15],[26],"MBF",[28],{"name":29,"affiliation":30,"role":31},"chun Wang","Go Broad Health Care","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Chun Wang","CONTACT","86-13386259777",null,"Wangchunsh@mefmail.com.cn",[40,59],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Rui Jin Hospital","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},[55],{"name":56,"role":35,"phone":57,"phoneExt":37,"email":58},"jiong HU","86-13764313546","hj10709@rjh.com.cn",{"facility":60,"status":61,"city":43,"state":44,"zip":37,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Zhaxin Hospital, Go Broad Health Care","NOT_YET_RECRUITING",{"type":49,"coordinates":63},[51,52],{"lat":52,"lon":51},[66],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":67},"wangchunsh@medmail.com.cn",{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"PRINCIPAL_INVESTIGATOR","Jiong HU","Deputy director, Department of Hematology",[73],{"name":74,"class":75},"Shanghai Clinical Research Center","UNKNOWN","100579836","phase-3-conditioning-regimen-of-melphalan-busulfan-and-fludarabine-a-randomized-study-of-different-dose-of-melphalan-100579836",false,"NCT06829472","Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan","Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomize Study Comparing 100mg\u002Fm2 to 140mg\u002Fm2 Melphalan for Adult Patients With Acute Myeloid Leukemia or Myelodysplasia Syndrome.","Inclusion Criteria:\n\n* Patients with AML in first remission\n* Patients with MDS with bone marrow blast \\>5% but remain less than 20% before transplantation\n* Donor available: HLA matched sibling donor, 9\\~10\u002F10 matched unrelated donor or haplo-identical donor\n* Inform consent provided\n\nExclusion Criteria:\n\n* Patients with active infection (bacteria, fungal or viral)\n* Patients with abnormal liver, renal and cardiac function","ALL","18 Years","55 Years",{"count":87,"type":88},120,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg\u002Fm2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML\u002FMDS receiving either MBF with 100 or 140 mg\u002Fm2 melphalan.",[94,95],"Toxicities","Survivorship",[97],"melphalan, AML, MDS, allogeneic stem cell transplantation","2025-02-14",{"date":100,"type":101},"2025-02-17","ACTUAL",{"date":103,"type":101},"2023-12-01",{"date":105,"type":88},"2026-12-01",{"name":5,"class":6},2]